Abstract
AimTranscervical fibroid ablation offers a non-invasive alternative to traditional surgical options for the treatment of symptomatic uterine fibroids using real-time visualization using intrauterine ultrasound guidance.Purpose of ReviewTo review the recent clinical literature on transcervical fibroid ablation (TFA) with the Sonata (R) System and discuss new developments in the use of such technology.Recent FindingsNearly six years since the Food and Drug Administration (FDA) approval in the United States (2018) and 14 years since receiving CE Mark in Europe, TFA with the Sonata system has been used to treat over 30,000 myomas in more than 10,000 procedures world-wide. Data regarding pregnancy outcomes, timing of pregnancy, route of delivery, neoadjuvant use of GnRH analogues and whether TFA is an effective treatment for adenomyosis remain fertile areas for investigation. Significant complications have been rarely reported.
TFA continues to be an increasingly adopted treatment modality that can safely address symptomatic uterine fibroids in a transcervical fashion. TFA provides a uterus-sparing, durable treatment associated with quick recovery, low re-intervention rates and high patient satisfaction. Preliminary findings support the use of TFA for additional treatment considerations, including adenomyosis and pregnancy outcomes. However, further research is needed to establish its efficacy and safety in these areas.